New Eli Lilly-backed neurological disease biotech Nido unveils with $109M

Nido Biosciences is exiting stealth with $109 million in hand to develop new precision medicines for neurological diseases and a lead asset that takes aim at Kennedy’s disease, a rare degenerative disorder.